Biogen on July 14, 2026 presented 18-month results from its Phase 2 CELIA trial of diranersen (BIIB080), an antisense oligonucleotide designed to lower production of the tau protein, at the Alzheimer's Association International Conference (AAIC) 2026 in London. In the 416-person trial, people with mild cognitive impairment or mild dementia due to Alzheimer's disease who received any of three tested doses of diranersen declined more slowly than those on placebo across several cognitive and functional measures, the company reported. Cath Mummery, the UCL and UCLH neurologist who presented the data, said the reduction in tau and the associated clinical results were among the most notable she had seen in Alzheimer's drug trials to date.

CELIA randomized participants, aged 50 to 80 and not previously treated with anti-amyloid drugs, to receive diranersen by spinal injection at 60 mg every 24 weeks, 115 mg every 24 weeks, or 115 mg every 12 weeks, or to placebo, over a 76-week treatment period. The lowest dose, given to 60 people, showed the largest effect: a 0.54-point, or 26 percent, slowing on the Clinical Dementia Rating-Sum of Boxes scale compared with the 115-person placebo group, alongside a 42 percent slowing on the ADAS-Cog13 cognitive test and 50 percent on the MMSE. All three doses produced reductions of 50 to 65 percent in cerebrospinal fluid tau and reduced tau signal on brain PET scans, which Biogen described as evidence the drug reached and lowered its target.

The trial did not meet its formal primary endpoint, which required a dose-response relationship in which higher doses would slow decline more than lower ones; instead, the lowest dose performed best, the opposite pattern. Biogen reported that serious adverse events were more frequent in the highest-dose group, though it said no cases of ARIA, the brain swelling or bleeding associated with anti-amyloid antibody drugs, occurred with diranersen. Most side effects were mild or moderate, including procedural pain, post-lumbar-puncture symptoms and short-lived confusion following the spinal injections, according to the company.

Biogen said it plans to move diranersen into Phase 3, confirmatory testing, building on the Fast Track designation the FDA granted the drug in 2025. It follows earlier coverage of Roche's decision to test its amyloid-targeting antibody trontinemab in people with no symptoms through the PrevenTRON prevention trial; diranersen instead targets tau, a different protein, in people already showing symptoms of early Alzheimer's disease.